Galmed (GLMD) announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of ...

NASH is the advanced stage of fatty liver disease, a condition largely caused ... must-attend opportunity to gain actionable strategies, real-world case studies, and expert insights to confidently ...

Impaired lysosomal function (breaking down waste) leads to accumulation of excess lipids in liver cells, worsening NAFLD and contributing to its progression. By analyzing a clinical gene-profiling ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...

The American Association for the Study of Liver Diseases (AASLD) is inviting members to apply as site principal investigators to participate in TARGET-LD, which broadly studies outcomes for patients ...

It encompasses a spectrum of diseases ranging from simple fatty liver to non-alcoholic steatohepatitis (NASH) and can progress ... implementing large-scale, real-world observational studies ...

The second stage is non-alcoholic steatohepatitis (NASH) when the liver starts to get inflamed ... False hunger disappears.

And we're seeing real progress as we've engaged ... informed the design of our ongoing MAESTRO-NASH outcomes trial. We believe that Rezdiffra's liver directed mechanism of action should deliver ...

Madrigal is conducting a Phase 3 outcomes trial (MAESTRO-NASH OUTCOMES ... Madrigal believes that Rezdiffra's “fast” onset and “liver-directed” mechanism differentiates it from GLP ...

The second stage is non-alcoholic steatohepatitis (NASH) when the liver starts ... False hunger disappears. Real hunger stays ...